Mittal Abhenil, Deo S V S, Gogia Ajay, Batra Atul, Kumar Akash, Bhoriwal Sandeep, Deb Koushik Sinha, Dhamija Ekta, Ramprasad V L, Olopade Olufunmilayo, Pramanik Raja
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India.
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India.
Ecancermedicalscience. 2022 Aug 1;16:1434. doi: 10.3332/ecancer.2022.1434. eCollection 2022.
The spectrum and significance of Variants of Uncertain Significance (VUS) mutations in breast cancer predisposition genes is poorly defined in the Indian population.
All new female breast cancer patients from 1 March 2019 to 28 February 2020 were screened. Those providing informed consent and without previous genetic testing were recruited. Multigene panel testing (107 genes) by next-generation sequencing was performed for all patients. Descriptive statistics was used to describe the spectrum of VUS mutations.
Out of 236 patients recruited in the study, a VUS was detected in 89 patients (37.71%). VUS pathogenic ratio was 2.02. A total of 121 different VUS mutations in 40 different genes were detected. Fourteen patients (15.7%) had a VUS in high penetrance genes and 36 VUS mutations (29.8%) were detected in one of the genes involved in homologous recombination repair pathway. No therapeutic interventions were done based on VUS.
In this large prospective study of genetic determinants of breast cancer from India, a high prevalence of VUS (37.71%) was detected with 15.7% patients having a VUS in high penetrance genes. More evidence needs to be generated from larger multicentric studies to better understand the implications of these genetic variants and enable their reclassification.
在印度人群中,乳腺癌易感基因中意义未明变异(VUS)突变的谱型及意义尚不明确。
对2019年3月1日至2020年2月28日期间所有新诊断的女性乳腺癌患者进行筛查。招募那些提供知情同意且此前未进行过基因检测的患者。对所有患者进行二代测序多基因panel检测(107个基因)。采用描述性统计来描述VUS突变的谱型。
在本研究招募的236例患者中,89例(37.71%)检测到VUS。VUS致病率为2.02。共检测到40个不同基因中的121种不同的VUS突变。14例患者(15.7%)在高外显率基因中有VUS,36种VUS突变(29.8%)在参与同源重组修复途径的基因之一中被检测到。未基于VUS进行治疗干预。
在这项来自印度的关于乳腺癌遗传决定因素的大型前瞻性研究中,检测到VUS的高患病率(37.71%),15.7%的患者在高外显率基因中有VUS。需要从更大规模的多中心研究中获取更多证据,以更好地理解这些基因变异的影响并实现其重新分类。